Newsletters
EARLEANM Young Authors’ Award
Who can apply?
- The applicant must be no older than 38 years old.
- The applicant must be the first author of the presented work.
- The applicant must be an EANM junior or ordinary member.
- At least one of the authors of the paper must attend the EANM Annual Congress.
Application:
The applicant must indicate during the abstract submission process (by ticking the relevant box) that they would like to apply for this award. Once the applicant is shortlisted, the presenting author will be requested to scan and e-mail a copy of their passport or birth certificate as proof of age.
The deadline for the application will be the same as the abstract submission deadline for the EANM Annual Congress.
Selection Procedure:
Once the abstract submission period has ended, the review process will begin. After reviewing, the approximately 15 highest-rated papers submitted for the EANM Young Authors’ Award will be shortlisted. These shortlisted abstracts will be anonymised and sent to the EANM Scientific Programme Committee. The 3 top-rated papers will receive the EANM Young Authors’ Award.
Overview over past winners
Molecular imaging predicts response absence to T-DM1 in advanced HER2-positive breast cancer: final results from a prospective phase II ZEPHIR trial
Mileva1, E. G. de Vries2, T. Guiot3, Z. Wimana4, A. Deleu1, C. Schröder5,6, Y. Lefebvre1, M. Paesmans7, S. Stroobants8, M. Huizing9, P. Aftimos10, J. Tol11, W. Van der Graaf12, W. Oyen13,14,15, D. Vugts16, C. Menke-van der Houven van Oordt12, A. Brouwers17, M. Piccart-Gebhart10, P. Flamen1, G. Gebhart1;
1Department of Nuclear Medicine, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 2Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, Groningen, NETHERLANDS, 3Department of Medical Physics, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 4Department of Radiopharmacy, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 5Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS, 6Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, NETHERLANDS, 7Data center, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 8Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, 9Department of Medical Oncology, Antwerp University Hospital, Edegem, Antwerp, BELGIUM, 10Department of Medical Oncology, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, BELGIUM, 11Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands, Den Bosch, NETHERLANDS, 12Department of Medical Oncology, Amsterdam UMC location VUMC, Cancer Centre Amsterdam, Amsterdam, NETHERLANDS, 13Humanitas Clinical and Research Center, Humanitas University, Milan, ITALY, 14Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, NETHERLANDS, 15Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS, 16Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, NETHERLANDS, 17Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.
PSMA and FDG PET as Predictive and Prognostic Biomarkers in Men with Metastatic, Castration-Resistant Prostate Cancer (mCRPC): an Analysis of the Randomised, Phase 2 Trial of [177Lu]Lu-PSMA-617 Versus Cabazitaxel (TheraP, ANZUP 1603)
J. Buteau1, A. Martin2, L. Emmett3, A. Iravani4, S. Sandhu1, A. M. Joshua3, R. J. Francis5, A. Y. Zhang2, A. M. Scott6, S. Lee6, A. Azad1, M. McJannett7, M. R. Stockler8, S. Williams1, I. D. Davis9, M. S. Hofman1;
1Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, 2NHMRC Clinical Trials Centre, Sydney, AUSTRALIA, 3St-Vincent’s Hospital, Sydney, AUSTRALIA, 4Washington University, St. Louis, MO, UNITED STATES OF AMERICA, 5Sir Charles Gairdner Hospital, Perth, AUSTRALIA, 6Austin Health, Melbourne, AUSTRALIA, 7ANZUP, Sydney, AUSTRALIA, 8NHMRC CTC, Sydney, AUSTRALIA, 9Monash University and Eastern Health, Melbourne, AUSTRALIA.
Next generation PET/CT imaging in meningioma using the novel SSTR-targeting peptide 18F-SiTATE – first clinical experiences
M. Unterrainer1, S. C. Kunte1, L. M. Unterrainer1, A. Delker1, S. Lindner1, M. Brendel1, A. Holzgreve1, W. G. Kunz1, C. C. Cyran1, J. Ricke1, K. Jurkschat2, C. Waengler3, B. Waengler3, R. Schirrmacher4, M. Niyazi1, J. Tonn1, L. Beyer1, P. Bartenstein1, N. L. Albert1;
1University of Munich, Munich, GERMANY, 2TU Dortmund, Dortmund, GERMANY, 3University of Heidelberg, Heidelberg, GERMANY, 4University of Alberta, Edmonton, AB, CANADA.
[18F]AlF-NOTA-octreotide vs. [68Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective multicentre trial
E. Pauwels1, F. Cleeren2, T. Tshibangu2, M. Koole1, K. Serdons1, L. Boeckxstaens1, J. Dekervel3, T. Vandamme4,5, W. Lybaert5, B. Van den Broeck6, P. M. Clement7, K. Geboes8, E. Van Cutsem3, S. Stroobants9, C. Verslype3, G. Bormans2, C. M. Deroose1;
1Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, 2Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, 3Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM, 4Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM, 5Oncology, NETwerk Antwerpen-Waasland CoE, Antwerpen, BELGIUM, 6Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM, 7General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM, 8Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM, 9Nuclear Medicine, Antwerp University Hospital; Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.
Longitudinal Evaluation Of The First Mutant Huntingtin PET Radioligand As A Marker For mHTT Lowering Therapies For Huntington’s Disease
D. Bertoglio1, J. Verhaeghe1, S. De Lombaerde1,2, F. Zajicek1, T. Vasilkovska1, A. Miranda3, A. Gaertner4, B. Huscher4, A. Kakoulidou4, I. Cardaun4, A. Cornelius4, T. Schwagarus4, A. Van der Linden1, S. Stroobants1,2, Y. Wang5, M. Skinbjerg5, C. Dominguez5, V. Khetarpal5, L. Liu5, I. Munoz-Sanjuan5, J. Bard5, S. Staelens1;
1University of Antwerp, Wilrijk, BELGIUM, 2Antwerp University Hospital, Edegem, BELGIUM, 3University of Antwerp, Antwerpen, BELGIUM, 4Evotec SE, Hamburg, GERMANY, 5CHDI Management/CHDI Foundation, Los Angeles, CA, UNITED STATES OF AMERICA.
A pilot study comparing 18F-FDG PET/CT and 68Ga-FAPI PET/CT for initial staging of early operable and locally advanced breast cancers
P. Chandra, K. Senthil, M. Sridev, G. Chandran, J. Kumar, M. Merlin, P. Priya, J. Sangeetha, S. Nath;
MIOT international, Chennai, INDIA.
68Ga-FAPI-04 PET/CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-related interstitial lung disease
C. Schmidkonz1, J. Distler2, C. Treutlein3, A. Atzinger1, O. Prante1, P. Ritt1, T. Götz1, T. Bäuerle1, M. Cordes1, M. Köhner1, T. Kuwert1, A. Ramming2, G. Schett2, C. Bergmann2;
1University Hospital Erlangen, Department of Nuclear Medicine, Erlangen, GERMANY, 2University Hospital Erlangen, Department of Rheumatology, Erlangen, GERMANY, 3University Hospital Erlangen, Department of Radiology, Erlangen, GERMANY.
Ratiometric relationship between γH2AX imaging and Lutetium-177 is predictive of survival following radionuclide therapy in vivo
E. O’Neill, G. M. Dias, B. Cornelissen;
University of Oxford, Oxford, UNITED KINGDOM.
[18F]AlF-NOTA-octreotide PET imaging: Pharmacokinetics, biodistribution, and head-to-head comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients
E. Pauwels1, F. Cleeren2, T. Tshibangu2, M. Koole1, K. Serdons1, J. Dekervel3, E. Van Cutsem3, C. Verslype3, K. Van Laere1, G. Bormans2, C. M. Deroose1;
1Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, 2Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, 3Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM.
[177Lu]Lu-PSMA-617 in low-volume metastatic hormone sensitive prostate cancer: a prospective pilot study
B. Prive1, S. M. B. Peters1, C. H. J. Muselaers1, P. Zamecnik1, M. J. R. Janssen1, T. W. J. Scheenen1, M. W. Konijnenberg1, J. Verzijlbergen1, W. R. Gerritsen1, N. Mehra1, D. M. Somford2, J. A. Van Basten2, I. M. Van Oort1, J. Sedelaar1, J. O. Barentsz1, S. Heskamp1, M. Gotthardt1, J. Witjes1, J. Nagarajah1;
1Radboudumc, Nijmegen, NETHERLANDS, 2Canisius Wilhelmina Hospital, Nijmegen, NETHERLANDS.
Fluorine-18 Labeled FAPI-Tracers For PET Imaging
T. Lindner1, A. Altmann1,2, F. L. Giesel1, C. Kratochwil1, C. Kleist1, S. Kraemer1, J. Debus3,4, W. Mier1, U. Haberkorn1,2,5;
1Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, 2Clinical Cooperation Unit Nuclear Medicine, German Cancer research Center (DKFZ), Heidelberg, GERMANY, 3Dept. of Radiation Oncology, University Hospital Heidelberg, Heidelberg, GERMANY, 4Clinical Cooperation Unit Radiation Oncology, German Cancer research Center (DKFZ), Heidelberg, GERMANY, 5Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, GERMANY.
First Results of Targeted Alpha Peptide Receptor Radionuclide Therapy Using Ac-225 DOTATOC for Progressive Metastatic Neuroendocrine Neoplasms
H. R. Kulkarni, J. Zhang, A. Singh, C. Schuchardt, R. P. Baum;
THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, GERMANY.
Tandem PSMA Radioligand Therapy Using Ac-225 and Lu-177 in Advanced Prostate Cancer: Safety and Efficacy
H. R. Kulkarni, J. Zhang, A. Singh, A. Mishra, C. Schuchardt, R. P. Baum;
THERANOSTICS Center for Molecular Radiotherapy and Precision Oncology, Zentralklinik Bad Berka, Bad Berka, GERMANY.
Imaging DNA Damage in vivo following [177Lu]Lu-DOTATATE therapy in a model of pancreatic neuroendocrine cancer
E. O’Neill1, V. Kersemans1, P. Allen1, S. Terry2, J. Baguña Torres1, S. Smart1, B. Quan Lee1, N. Falzone1, K. Vallis1, M. Konijnenberg3, M. de Jong3, J. Nonnekens3, B. Cornelissen1;
1University of Oxford, Oxford, UNITED KINGDOM, 2King’s College London, London, UNITED KINGDOM, 3Erasmus MC, Rotterdam, NETHERLANDS.
First extensive preclinical evaluation of PSMA-specific tracers for prostate cancer radioligand therapy
E. Ruigrok, S. U. Dalm, E. de Blois, N. van Vliet, D. C. van Gent, J. Haeck, C. de Ridder, D. Stuurman, M. W. Konijnenberg, W. M. van Weerden, M. de Jong, J. Nonnekens;
Erasmus MC, Rotterdam, NETHERLANDS.
Clinical outcome of 121 patients after PSMA-targeted radioguided surgery for early biochemical recurrent prostate cancer
M. Kroenke1, T. Horn2, I. Rauscher1, S. Robu3, M. Schottelius3, H. Wester3, T. Maurer2, W. Weber1, M. Eiber1;
1Department of Nuclear medicine, Klinikum rechts der Isar, TUM, Munich, GERMANY, 2Department of Urology, Klinikum rechts der Isar, TUM, Munich, GERMANY, 3Chair of Pharmaceutical Radiochemistry, Department of Chemistry, TUM, Munich, GERMANY.
A Complete Response following A Single Treatment with 225Ac-RPS-074 in LNCaP Xenografts
J. M. Kelly1, A. Amor-Coarasa1, S. Ponnala1, N. A. Thiele2, A. Nikolopoulou1, C. Williams Jr.1, J. Urgiles1, J. J. Wilson2, J. W. Babich1;
1Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA, 2Cornell University, Ithaca, NY, UNITED STATES OF AMERICA.
First evidence for a dose-response relationship in hepatic holmium-166 radioembolization
R. Bastiaannet, C. van Roekel, M. L. J. Smits, R. C. G. Bruijnen, J. F. Prince, H. W. A. M. de Jong, M. G. E. H. Lam; ;
University Medical Center Utrecht, Utrecht, NETHERLANDS.
Development Of Stroma-targeted Theranostics Based On Inhibitors Of Fibroblast Activating Protein
T. Lindner, A. Loktev, A. Altmann, F. Giesel, C. Kratochwil, W. Mier, U. Haberkorn;
University Hospital Heidelberg, Heidelberg, GERMANY.
Novel targeted radionuclide therapy approach enhances response to immune checkpoint blockade in murine melanoma
R. Hernandez, R. Patel, J. Grudzinski, E. Aluicio-Sarduy, R. Brown, R. Sriramaneni, J. W. Engle, P. M. Sondel, Z. S. Morris, J. P. Weichert;
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.
Dual-labeled PSMA-11 for PET/CT imaging and precise fluorescence guided intraoperative identification of prostate cancer
A. Baranski1, M. Schäfer1, U. Bauder-Wüst1, M. Roscher1, J. Schmidt1, E. Stenau1, T. Simpfendörfer2, L. Maier-Hein1, B. Hadaschik3, U. Haberkorn2, K. Kopka1, M. Eder4,1,5;
1German Cancer Research Center, Heidelberg, GERMANY, 2University Hospital, Heidelberg, GERMANY, 3University Hospital, Essen, GERMANY, 4University Hospital, Freiburg, GERMANY, 5German Cancer Consortium, Heidelberg, GERMANY.
First experience using LMI1195 in patients with the suspicion of pheochromocytoma or paraganglioma
C. Rischpler1, A. M. Schlitter1, M. Herz1, B. Yousefi1, A. von Werder1, R. Tauber1, T. Maurer1, K. Scheidhauer1, S. Robinson2, C. Orlandi2, S. G. Nekolla1, M. Schwaiger1;
1Technical University Munich, Munich, GERMANY, 2Lantheus Medical Imaging, N. Billerica, MA, UNITED STATES OF AMERICA.
TSPO-PET for high-grade glioma imaging using the novel ligand [18F]GE-180 – first in human results in the course of radiotherapy
M. Unterrainer1, D. Fleischmann1, S. Lindner1, A. Brunegraf1, F. Vettermann1, L. Vomacka1, M. Brendel1, R. Rupprecht2, C. Belka1, P. Bartenstein1, M. Niyazi1, N. Albert1;
1Ludwig-Maximilian-University Munich, München, GERMANY, 2University of Regensburg, München, GERMANY.
Monitoring tumor PD-L1 expression with microSPECT/CT during radiotherapy
S. Heskamp, J. D. M. Molkenboer-Kuenen, G. W. Sandker, P. J. Wierstra, J. Bussink, O. C. Boerman;
Radboud University Nijmegen Medical Centre, NIJMEGEN, NETHERLANDS.
Radiocobalt-labeled anti-HER1 affibody molecule DOTA-ZEGFR:2377 for imaging of low HER1 expression in prostate cancer pre-clinical model
B. Mitran1, J. Garousi1, M. Rosestedt1, E. Lindström1, K. G. Andersson2, S. Ståhl2, J. Löfblom2, V. Tolmachev1, A. Orlova1;
1Uppsala University, Uppsala, SWEDEN, 2KTH-Royal Institute of Technology, Stockholm, SWEDEN.
68Ga-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels < 2 ng/mL
F. Ceci, P. Castellucci, T. Graziani, C. Fonti, F. Lodi, S. Boschi, S. Fanti; Service of Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.
SPECT/CT imaging of the PD-1/PD-L1 immune checkpoint pathway in syngeneic murine tumor models
S. Heskamp, J. D. M. Molkenboer-Kuenen, R. H. A. M. van de Vondervoort, O. C. Boerman; Radboud University Nijmegen Medical Centre, NIJMEGEN, NETHERLANDS.
Feasibility of in vivo imaging of VEGFR2 expression using high affinity antagonistic biparatopic affibody construct ZVEGFR2-Bp2
B. Mitran1, R. Güler2, E. Lindström1, F. Fleetwood2, V. Tolmachev1, S. Ståhl2, A. Orlova1, J. Löfblom2; 1Uppsala University, Uppsala, SWEDEN, 2KTH Royal Institute of Technology, Stockholm, SWEDEN.
Prognostic significance of molecular and imaging biomarkers in primary brain tumors
E. Lopci1, M. Riva1, L. Olivari2, F. Raneri2, A. Bizzi3, B. Fernandes1, P. Navarria1, F. Pessina1, M. Roncalli4, L. Bello1, A. Chiti4; 1Humanitas Clinical and Research Hospital, Milano, ITALY, 2University of Milan, Milano, ITALY, 3Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, ITALY, 4Humanitas University, Milano, ITALY.
Value of F-DOPA PET in the long term follow up of radionecrotic brain metastases after radiosurgery: comparison with MRIF. Cicone1, L. Carideo1, C. Scaringi2, A. Romano3, A. Bozzao3, G. Minniti2, F. Scopinaro1; 1Unit of Nuclear Medicine, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, 2Unit of Radiation Oncology, Sant’Andrea Hospital, “Sapienza” University of Rome, Rome, ITALY, 3Unit of Neuroradiology, Sant’Andrea Hospital, “Sapienza” University or Rome, Rome, ITALY.
A phage display derived stabilised bicyclic peptide targeting MMP-14 shows high imaging contrast in small animal PET imaging
A. M. Eder, S. Pavan, U. Bauder-Wüst, K. van Rietschoten, L. Baldassarre, U. Schierbaum, O. Seibert, K. Leotta, S. Campbell, H. Harrison, C. Stace, E. Walker, U. Haberkor, K. Kopka, D. P. Teufel; Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
Tc-99m-CXCL8 SPECT to image disease activity in inflammatory bowel disease
E. Aarntzen, D. De Jong, R. Hermsen, J. Drenth, O. Boerman, W. Oyen; Radboud UMC, Nijmegen, Netherlands
Blunted striatal dopamine release in cannabis dependence
E. van de Giessen, J. Weinstein, C. Cassidy, M. Haney, M. Slifstein, A. Abi-Dargham; Columbia University College of Physicians and Surgeons/New York State Psychiatric Institute, New York, United States of America.
Synergistically Enhanced Tumor Uptake via Dual-Targeting of CD105 and EGFR Using a “Click” Heterodimer
R. Hernandez, H. Luo, H. Hong, S. A. Graves, R. J. Nickles, W. Cai; University of Wisconsin-Madison, Madison, United States of America.
Metastatic control probability in patients with prostate cancer metastatic to bone treated 186Re-HEDP
A. M. Denis-Bacelar, A. Divoli, S. Chittenden, Y. Du, G. D. Flux; Institute of Cancer Research, London, United Kingdom
Quantitative analyses at Baseline and Interim PET evaluation for response assessment and outcome definition in patients with Malignant Pleural Mesothelioma (MPM)
Egesta Lopci; Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), HUMANITAS (Rozzano), Milano, Italy
A comparison of EGFR-targeted and non-targeted 177Lu-labeled gold nanoparticles (AuNPs) for localized radiation treatment of breast cancer xenografts in athymic mice
Simmyung Yook; University of Toronto, Leslie Dan Faculty of Pharmacy, Pharmaceutical Sciences, Toronto, Canada
Validation and applications for SNAP-tag imaging of bacterial infection.
Bethany Mills; University of Nottingham, Nottingham, United Kingdom
Non-FDG-avid areas inside a tumour mass in Paediatric Hodgkin Lymphoma (PHL) patients – A new risk factor?
Lars Kurch; University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany
The QUEST Study: Correlating metabolic response with 90Y PET dosimetry for the treatment of metastatic liver cancer with radioembolisation
Kathy P. Willowson; University of Sydney, Sydney, Australia
Development and pre-clinical evaluation of a new glucose-dependent insulinotropic polypeptide (GIP) based radioligand for PET imaging of a broad spectrum of neuroendocrine tumors
Eleni Gourni; University Hospital, Department of Nuclear Medicine, Freiburg, GERMANY
Synergistic anti-cancer response to chemotherapy and 177Lu-labelled APOMAB® radio immunotherapy in a preclinical model of lung cancer
Alexander Staudacher; Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, AUSTRALIA
Tc99m labelled S-HYNIC Certolizumab Pegol for selecting patients for anti-TNFα treatment: a biodistribution and dosimetric study
Bieke Lambert; Department of Nuclear Medicine, Ghent University Hospital, BELGIUM
PET-guided radiotherapy planning in prostate cancer patients
Egesta Lopci; Humanitas Clinical and Research Center, Milan, ITALY
Evaluation of primary tumour and regional lymph node metastases with FDG PET/CT in breast cancer patients: prone versus supine position
Suzana Teixeira; Dutch Cancer Institute, Amsterdam, NETHERLANDS.